DSS, Inc. (NYSEAMERICAN:DSS – Get Free Report) Director Heng Fai Ambrose Chan bought 205,149 shares of DSS stock in a transaction on Tuesday, December 10th. The shares were acquired at an average cost of $0.97 per share, with a total value of $198,994.53. Following the completion of the acquisition, the director now owns 1,184,475 shares of the company’s stock, valued at $1,148,940.75. The trade was a 20.95 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is available at this hyperlink.
DSS Trading Up 6.8 %
Shares of DSS stock opened at $1.03 on Friday. The company has a debt-to-equity ratio of 0.11, a current ratio of 1.16 and a quick ratio of 1.11. DSS, Inc. has a 1 year low of $0.86 and a 1 year high of $3.08.
Institutional Trading of DSS
A hedge fund recently bought a new stake in DSS stock. Ferguson Wellman Capital Management Inc. acquired a new position in DSS, Inc. (NYSEAMERICAN:DSS – Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 25,501 shares of the business services provider’s stock, valued at approximately $32,000. Ferguson Wellman Capital Management Inc. owned approximately 0.36% of DSS at the end of the most recent reporting period. Institutional investors and hedge funds own 53.33% of the company’s stock.
DSS Company Profile
DSS, Inc operates in the product packaging, biotechnology, commercial lending, securities and investment management, alternative trading, and direct marketing businesses. It manufactures, markets, and sells mailers, photo sleeves, custom folding cartons, and 3-dimensional direct mail solutions; and markets and distributes nutritional and personal care products.
Featured Stories
- Five stocks we like better than DSS
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Why Hershey Stock Has More Room to Run Despite Takeover Rejection
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Texas Instruments: The Old-School Tech Titan Still Delivering
- Stock Average Calculator
- GRAIL: Biotech Stock Targeting $100B Cancer Market
Receive News & Ratings for DSS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DSS and related companies with MarketBeat.com's FREE daily email newsletter.